Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
View Session ViewAttendees 21
Meet-the-Professor

63 - Microbial Genomics: Ready for Prime Time?

Friday, October 1, 2021
10:00 AM - 11:15 AM EDT

    Moderator(s)

  • Anne-Catrin Uhlemann, MD, PhD

    Associate Professor
    Medicine/Infectious Diseases
    Columbia University Irving Medical Center
    New York, NY, United States

    Merck (Individual(s) Involved: Self): Grant/Research Support

  • Michael Glickman, MD, FIDSA, FAAM

    Member, Attending Physician
    Memorial Sloan Kettering
    New York, NY, United States

    Fimbrion Therapeutics (Individual(s) Involved: Self): Consultant; Pathogen Response Lab (Individual(s) Involved: Self): Board Member; Vedanta Biosciences (Individual(s) Involved: Self): Board Member, Shareholder

    • Speaker(s)

  • Gautam Dantas, PhD

    Professor
    Pathology and Immunology
    Washington University School of Medicine in St Louis
    St. Louis, MO, United States

    Pluton Biosciences (Individual(s) Involved: Self): Advisor or Review Panel member; SNIPR Technologies Ltd (Individual(s) Involved: Self): Consultant; Viosera Therapeutics (Individual(s) Involved: Self): Board Member, Shareholder

  • Sharon Peacock, MRCP, MRCPath, PhD

    Professor of Public Health and Microbiology
    University of Cambridge
    Cambridge, United Kingdom

    Next Gen Diagnostics (Individual(s) Involved: Self): Advisor or Review Panel member, Shareholder; Pfizer (Individual(s) Involved: Self): Advisor or Review Panel member; Specific (Individual(s) Involved: Self): Advisor or Review Panel member, Shareholder

Participants should be aware of the following financial/non-financial relationships:
Anne-Catrin Uhlemann, MD, PhD: Merck (Individual(s) Involved: Self): Grant/Research Support
Michael S. Glickman, MD, FIDSA, FAAM: Fimbrion Therapeutics (Individual(s) Involved: Self): Consultant; Pathogen Response Lab (Individual(s) Involved: Self): Board Member; Vedanta Biosciences (Individual(s) Involved: Self): Board Member, Shareholder
Gautam Dantas, PhD: Pluton Biosciences (Individual(s) Involved: Self): Advisor or Review Panel member; SNIPR Technologies Ltd (Individual(s) Involved: Self): Consultant; Viosera Therapeutics (Individual(s) Involved: Self): Board Member, Shareholder
Sharon Peacock, MRCP, MRCPath, PhD: Next Gen Diagnostics (Individual(s) Involved: Self): Advisor or Review Panel member, Shareholder; Pfizer (Individual(s) Involved: Self): Advisor or Review Panel member; Specific (Individual(s) Involved: Self): Advisor or Review Panel member, Shareholder

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit

No CPE credits

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • describe genomic approaches to identify anti-microbial resistance
  • explain how routine whole genome sequencing can be leveraged in the clinical microbiology lab
  • explain the utility of whole genome sequencing in public health

Presentations:

  • Sequence- and Function-based Methods and Resources to Study Antimicrobial Resistance

    Speaker: Gautam Dantas, PhD – Washington University School of Medicine in St Louis

  • Transforming the Translation of Pathogen Sequencing into Practice in the Wake of COVID-19

    Speaker: Sharon Peacock, MRCP, MRCPath, PhD – University of Cambridge